BETADINE® is a metaphor for the growth of the consumer healthcare business and the opportunity this presents for Singapore.
Trusted in homes, as well as hospitals, worldwide for more than five decades, BETADINE® consumer healthcare products containing Povidone-iodine (PVPI) have been proven in in-vitro studies to kill viruses that cause the spread of infectious diseases such as MERS, Ebola, SARS, influenza and HFMD. Global R&D for BETADINE® has been moved to Singapore to support the world.
As living standards and healthcare expectations rise across the world, demand for BETADINE® products containing PVPI is projected to double in the next five years, with Asia, Middle East and Africa responsible for the great majority of this growth. Asia alone is now projected to consume 70% of total unit demand.
This explosion in demand frames Singapore’s opportunity to steward the growth of the global pharma sector as emerging markets mature – one it’s well equipped to realise.
In fact, Mundipharma projects that Singapore will become the consumer health hub for Asia, Middle East and Africa. There are several well-publicised benefits, not least the access to world-class talent, logistics and Singapore’s renowned legal and corporate governance.
Fundamentally, it comes down to proximity to an ever-expanding market, where Singapore’s attributes make it possible to provide more people with access to medicines at efficient pricing.
A further benefit from proximity to markets is the quick supply of BETADINE® products containing PVPI should there be a significant outbreak of an infectious disease, such as MERS, Ebola, Influenza and SARS. A Singapore hub will further increase the speed of support.
The ‘BETADINE® Effect’ coupled with Singapore’s competitive advantages is prompting Mundipharma to double down on Singapore as its global research and development, manufacturing and logistics hub.
We have invested in a new world-class facility in Tuas Singapore, which will be operational this year. It is built to modern green building standards, to help minimise waste and power usage, and includes:
- State-of-the-art global R&D centre – focused on extending the BETADINE® product range as well developing new innovative treatment options for the growing Asian market
- Manufacturing operations –Singapore is an excellent site for manufacturing due to its proximity to locations that have experienced infectious disease outbreaks
- Logistics and distribution – leveraging Singapore’s air and sea network hub for all consumer products